CLL Coverage from Every Angle
Advertisement
Advertisement

Alexey V. Danilov, MD, PhD, on Ibrutinib, Acalabrutinib, and Other Agents for CLL: Expert Perspective on Benefits and Risks

Posted: Wednesday, August 25, 2021

Alexey V. Danilov, MD, PhD, of City of Hope, discusses the agents approved for use as first-line treatment of chronic lymphocytic leukemia, other classes of agents that may be used in combination with a BTK inhibitor, and some clinical pearls on the drugs’ activity and side effects.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.